Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.

MLA

Nelson, Adam J., et al. “Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.” Circulation, vol. 144, no. 1, July 2021, pp. 74–84. EBSCOhost, https://doi.org/10.1161/CIRCULATIONAHA.121.053766.

APA

Nelson, A. J., Pagidipati, N. J., Aroda, V. R., Cavender, M. A., Green, J. B., Lopes, R. D., Al-Khalidi, H., Gaynor, T., Kaltenbach, L. A., Kirk, J. K., Lingvay, I., Magwire, M. L., O’Brien, E. C., Pak, J., Pop-Busui, R., Richardson, C. R., Reed, M., Senyucel, C., Webb, L., & McGuire, D. K. (2021). Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. Circulation, 144(1), 74–84. https://doi.org/10.1161/CIRCULATIONAHA.121.053766

Chicago

Nelson, Adam J., Neha J. Pagidipati, Vanita R. Aroda, Matthew A. Cavender, Jennifer B. Green, Renato D. Lopes, Hussein Al-Khalidi, et al. 2021. “Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.” Circulation 144 (1): 74–84. doi:10.1161/CIRCULATIONAHA.121.053766.